INCY
Incyte Corporation
NASDAQ: INCY · HEALTHCARE · BIOTECHNOLOGY
$95.27
-3.86% today
Updated 2026-04-30
Market cap
$19.80B
P/E ratio
14.00
P/S ratio
3.69x
EPS (TTM)
$7.08
Dividend yield
—
52W range
$58 – $112
Volume
1.6M
Incyte Corporation (INCY) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
+11.0%
Last 4 quarters
Revenue YoY growth
+27.8%
Most recent quarter
EPS YoY growth
+25.9%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.6%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+10.5%
2025-07-29
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-10 | $1.80 | -5.8% | $109.03 | $98.84 | -9.3% |
| 2025-10-28 | $2.26 | +37.8% | $93.08 | $90.18 | -3.1% |
| 2025-07-29 | $1.57 | +6.8% | $70.16 | $77.55 | +10.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $1.91 | $1.80 | -5.8% | $1.51B | +27.8% |
| 2025-09-30 | $1.64 | $2.26 | +37.8% | $1.37B | +20.0% |
| 2025-06-30 | $1.47 | $1.57 | +6.8% | $1.22B | +16.5% |
| 2025-03-31 | $0.76 | $0.80 | +5.3% | $1.05B | +19.5% |
| 2024-12-31 | $1.55 | $1.43 | -7.7% | $1.18B | +16.3% |
| 2024-09-30 | $0.79 | $0.54 | -31.6% | $1.14B | +23.8% |
| 2024-06-30 | $-1.55 | $-1.82 | -17.4% | $1.04B | +9.3% |
| 2024-03-31 | $0.84 | $0.64 | -23.8% | $880.89M | — |
| 2023-12-31 | $1.16 | $1.06 | -8.6% | $1.01B | — |
| 2023-09-30 | $1.02 | $1.10 | +7.8% | $919.02M | — |
| 2023-06-30 | $0.83 | $0.99 | +19.3% | $954.61M | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $7.66 | $5.7B | +11.0% | 21 | high |
| 2027 (E) | $8.98 | $6.4B | +11.3% | 21 | high |
| 2028 (E) | $10.65 | $7.2B | +12.6% | 21 | medium |
| 2029 (E) | $12.58 | $8.3B | +15.6% | 21 | medium |
Frequently asked questions
Has Incyte Corporation beaten earnings estimates?
Incyte Corporation has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of +11.0% over the last 4 quarters.
How does INCY stock react to earnings?
INCY stock has moved an average of -0.6% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Incyte Corporation's revenue growth rate?
Incyte Corporation reported year-over-year revenue growth of +27.8% in its most recent quarter, with EPS growing +25.9% year-over-year.
What is the expected EPS for INCY in 2026?
Analysts expect Incyte Corporation to report EPS of $7.66 for fiscal year 2026, on revenue of $5.7B, based on estimates from 21 analysts.